Abstract
The possibility to use a family donor sharing only one haplotype with recipient affected by hematological malignancy has been searched from many years because it allows having a donor in every case for every patient. At the beginning, this kind of transplantation was considered too toxic, but after the development of specific strategies of conditioning regimens and ex vivo T-cell depletion, its feasibility and efficacy has been proved, mainly for acute leukemia. However, these haploidentical programs with ex vivo T-cell depletion need of sophisticated and dedicated laboratories and are characterized by frequent infectious complications and relapse, because of delayed immune reconstitution. For these reasons, many groups have developed alternative program for haploidentical transplantation, without ex vivo T-cell depletion, obtaining encouraging results in haematological malignancies. In this review, we analyze data produced by different groups, underscoring their principal characteristics.
| Original language | French |
|---|---|
| Pages (from-to) | 1141-1151 |
| Number of pages | 11 |
| Journal | Bulletin du Cancer |
| Volume | 99 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 2012 |
Fingerprint
Keywords
- Haploidentical transplantation
- Hematological malignancies
- Myeloablative conditioning regimens
- Reduced intensity conditioning regimens
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Radiology Nuclear Medicine and imaging
- Hematology
Cite this
Développement des greffes haplo-identiques chez l'adulte atteint d'une hémopathie maligne. / Castagna, Luca; Blaise, Didier.
In: Bulletin du Cancer, Vol. 99, No. 12, 12.2012, p. 1141-1151.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Développement des greffes haplo-identiques chez l'adulte atteint d'une hémopathie maligne
AU - Castagna, Luca
AU - Blaise, Didier
PY - 2012/12
Y1 - 2012/12
N2 - The possibility to use a family donor sharing only one haplotype with recipient affected by hematological malignancy has been searched from many years because it allows having a donor in every case for every patient. At the beginning, this kind of transplantation was considered too toxic, but after the development of specific strategies of conditioning regimens and ex vivo T-cell depletion, its feasibility and efficacy has been proved, mainly for acute leukemia. However, these haploidentical programs with ex vivo T-cell depletion need of sophisticated and dedicated laboratories and are characterized by frequent infectious complications and relapse, because of delayed immune reconstitution. For these reasons, many groups have developed alternative program for haploidentical transplantation, without ex vivo T-cell depletion, obtaining encouraging results in haematological malignancies. In this review, we analyze data produced by different groups, underscoring their principal characteristics.
AB - The possibility to use a family donor sharing only one haplotype with recipient affected by hematological malignancy has been searched from many years because it allows having a donor in every case for every patient. At the beginning, this kind of transplantation was considered too toxic, but after the development of specific strategies of conditioning regimens and ex vivo T-cell depletion, its feasibility and efficacy has been proved, mainly for acute leukemia. However, these haploidentical programs with ex vivo T-cell depletion need of sophisticated and dedicated laboratories and are characterized by frequent infectious complications and relapse, because of delayed immune reconstitution. For these reasons, many groups have developed alternative program for haploidentical transplantation, without ex vivo T-cell depletion, obtaining encouraging results in haematological malignancies. In this review, we analyze data produced by different groups, underscoring their principal characteristics.
KW - Haploidentical transplantation
KW - Hematological malignancies
KW - Myeloablative conditioning regimens
KW - Reduced intensity conditioning regimens
UR - http://www.scopus.com/inward/record.url?scp=84872362240&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872362240&partnerID=8YFLogxK
U2 - 10.1684/bdc.2012.1665
DO - 10.1684/bdc.2012.1665
M3 - Articolo
C2 - 23220039
AN - SCOPUS:84872362240
VL - 99
SP - 1141
EP - 1151
JO - Bulletin du Cancer
JF - Bulletin du Cancer
SN - 0007-4551
IS - 12
ER -